Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Women currently using or starting a combined oral contraceptive (COC) will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for approximately 12 months to evaluate if they continue the implant, the COC, or both, and to assess bleeding patterns and adverse events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Davis
• Collaborators: Merck Sharp & Dohme Corp.; University of Colorado, Denver; University of Pennsylvania
• Treatments: Contraceptive Agents; Etonogestrel

Criteria

Inclusion Criteria:

• Women 18 years and older currently using COCs or who have a COC prescription and are intending to initiate COCs for contraception

Exclusion Criteria:

• Women who have contraindications to using a COC or a contraceptive implant (Category 3 or 4 in the CDC Medical Eligibility Criteria [MEC])

• Because the CDC MEC are continuously revised, the most updated criteria will be used (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a3.htm)

• Women who are currently participating in a clinical trial or have participated within the past 30 days.

• Less than 2 weeks from the end of a pregnancy.